Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
NCT06052345 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-03-05
Summary
This is a single center prospective observational cohort study that aims to:
* examine and identify possible risk and susceptibility factors for the incidence and progression of chemotherapy-induced polyneuropathy (CIPN) in female patients primarily operated for early non-metastatic breast cancer who will receive adjuvant chemotherapy containing paclitaxel
* test different neurophysiological methods for early detection of CIPN
* explore changes that underlie the development of CIPN in relation to clinical presentations, neurophysiological assessment, including measures of small nerve fiber dysfunction, and possible biochemical, metabolic and genetic associations
* explore the effects of CIPN in the patient's lifestyle and quality of life for up to 12 months after the initiation of treatment
Conditions
- Breast Neoplasms
- Breast Cancer
- Early-stage Breast Cancer
- Non-Metastatic Breast Carcinoma
- Polyneuropathy Due to Drugs
- Polyneuropathy; Drug
- Chemotherapy-induced Peripheral Neuropathy
- Quality of Life
Interventions
- DEVICE
-
Garmin smartwatch
* Physical activity (Activity sessions, type and length of activity, activity intensity estimations) * Meal detection and meal characteristics (accelerometry and gyroscope data) * Oxygen saturation (pulse oximetry) * Number of steps (pedometer) * Stress level indicators (based on heart-rate analytics) * Sleep patterns (sleep and wake-up time, sleep quality)
- OTHER
-
REBECCA Mobile application
* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection) * Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3 * Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)
- OTHER
-
REBECCA PC plug-in
* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram). * These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites
Sponsors & Collaborators
- collaborator OTHER
-
Centre for Research and Technology Hellas (CERTH)
collaborator UNKNOWN -
Theodoros Foukakis
lead OTHER
Principal Investigators
-
Theodoros Foukakis, MD, PhD · Karolinska University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-31
- Primary Completion
- 2025-12-31
- Completion
- 2026-12-31
Countries
- Sweden
Study Locations
More Related Trials
-
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
NCT04222790 ·Status: COMPLETED ·Phase: PHASE2
-
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT04001829 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer
NCT01153282 ·Status: COMPLETED
-
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
NCT06135493 ·Status: COMPLETED ·Phase: PHASE2
-
Endocrine Disruptors and Life STILe in Breast Cancer Development
NCT05748353 ·Status: ACTIVE_NOT_RECRUITING
-
Chemotherapy-Induced Peripheral Neuropathy Survey
NCT01016028 ·Status: WITHDRAWN
-
Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer
NCT04068090 ·Status: UNKNOWN
-
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
NCT01190345 ·Status: COMPLETED ·Phase: PHASE2
-
Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
NCT06819501 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
NCT01982591 ·Status: COMPLETED
-
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT05751668 ·Status: SUSPENDED ·Phase: PHASE2
-
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
NCT00191438 ·Status: COMPLETED ·Phase: PHASE3
-
Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients
NCT03429972 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
NCT00378313 ·Status: COMPLETED ·Phase: PHASE2
-
Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer
NCT04205071 ·Status: WITHDRAWN ·Phase: PHASE1
-
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
NCT00618657 ·Status: COMPLETED ·Phase: PHASE2
-
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
NCT00003095 ·Status: COMPLETED
-
Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
NCT01352494 ·Status: UNKNOWN ·Phase: PHASE2
-
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
NCT00957125 ·Status: UNKNOWN ·Phase: PHASE2
-
Relationship Between Serum Interleukin-20 Level and Paclitaxel-associated Neuropathy
NCT05622617 ·Status: UNKNOWN
-
Study to Evaluate Markers of Response in Locally Advanced Breast Cancer
NCT01338753 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483 ·Status: RECRUITING
-
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
NCT00746694 ·Status: COMPLETED
-
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
NCT02789332 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT02999477 ·Status: COMPLETED ·Phase: PHASE1